| Print
Anavex Life Sciences Corp (AVXL)
Common SharesThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Company profile
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer'sdisease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and severalother compounds in different stages of clinical and pre-clinical development.
Address
51 West 52nd Street
7th Floor
New York
NY
USA
10019
Telephone
+1 844 6893939
Forecast key dates
| Name | Key Date |
|---|---|
| Anavex Life Sciences Corp Fourth Quarter Earnings Conference Call for 2026 | 2026-11-25T08:30:00 |
| Anavex Life Sciences Corp Fourth Quarter Earnings Results for 2026 | 2026-11-25T00:00:00 |
| Anavex Life Sciences Corp Annual Report for 2026 | 2026-11-25T00:00:00 |
| Anavex Life Sciences Corp Third Quarter Earnings Conference Call for 2026 | 2026-08-12T08:30:00 |
| Anavex Life Sciences Corp Third Quarter Earnings Results for 2026 | 2026-08-12T00:00:00 |
| Anavex Life Sciences Corp Annual General Meeting for 2026 | 2026-06-10T10:00:00 |
| Anavex Life Sciences Corp Second Quarter Earnings Conference Call for 2026 | 2026-05-13T08:30:00 |
| Anavex Life Sciences Corp Second Quarter Earnings Results for 2026 | 2026-05-13T00:00:00 |
| Anavex Life Sciences Corp First Quarter Earnings Conference Call for 2026 | 2026-02-12T08:30:00 |
| Anavex Life Sciences Corp First Quarter Earnings Results for 2026 | 2026-02-12T00:00:00 |
| The 44TH ANNUAL J.P. MORGAN Healthcare Conference | 2026-01-14T16:30:00 |
Previous key dates
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2025 AJ Bell. All rights reserved.